MDT Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 11.83% compared to Medtronic PLC's net margin of 14.45%. Medtronic PLC's return on equity of 9.51% beat Boston Scientific's return on equity of 9.57%.

Medtronic PLC has a consensus price target of $96.73, signalling upside risk potential of 8.2%. On the other hand Boston Scientific has an analysts' consensus of $117.45 which suggests that it could grow by 13.09%. Given that Boston Scientific has higher upside potential than Medtronic PLC, analysts believe Boston Scientific is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.804, which suggesting that the stock is 19.64% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.134%.

Medtronic PLC has a quarterly dividend of $0.71 per share corresponding to a yield of 3.14%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 76.98% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.9B, which are larger than Boston Scientific quarterly revenues of $4.7B. Medtronic PLC's net income of $1.1B is higher than Boston Scientific's net income of $674M. Notably, Medtronic PLC's price-to-earnings ratio is 24.70x while Boston Scientific's PE ratio is 75.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.44x versus 8.81x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 11.83% compared to Medtronic PLC's net margin of 30.99%. Medtronic PLC's return on equity of 9.51% beat Intuitive Surgical's return on equity of 15.82%.

Medtronic PLC has a consensus price target of $96.73, signalling upside risk potential of 8.2%. On the other hand Intuitive Surgical has an analysts' consensus of $578.35 which suggests that it could grow by 9.94%. Given that Intuitive Surgical has higher upside potential than Medtronic PLC, analysts believe Intuitive Surgical is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.804, which suggesting that the stock is 19.64% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.642, suggesting its more volatile than the S&P 500 by 64.249%.

Medtronic PLC has a quarterly dividend of $0.71 per share corresponding to a yield of 3.14%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 76.98% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.9B, which are larger than Intuitive Surgical quarterly revenues of $2.3B. Medtronic PLC's net income of $1.1B is higher than Intuitive Surgical's net income of $698.4M. Notably, Medtronic PLC's price-to-earnings ratio is 24.70x while Intuitive Surgical's PE ratio is 77.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.44x versus 21.91x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 11.83% compared to Medtronic PLC's net margin of 11.15%. Medtronic PLC's return on equity of 9.51% beat Stryker's return on equity of 14.2%.

Medtronic PLC has a consensus price target of $96.73, signalling upside risk potential of 8.2%. On the other hand Stryker has an analysts' consensus of $422.35 which suggests that it could grow by 6.99%. Given that Medtronic PLC has higher upside potential than Stryker, analysts believe Medtronic PLC is more attractive than Stryker.

Medtronic PLC has a beta of 0.804, which suggesting that the stock is 19.64% less volatile than S&P 500. In comparison Stryker has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.528%.

Medtronic PLC has a quarterly dividend of $0.71 per share corresponding to a yield of 3.14%. Stryker offers a yield of 0.84% to investors and pays a quarterly dividend of $0.84 per share. Medtronic PLC pays 76.98% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.9B, which are larger than Stryker quarterly revenues of $5.9B. Medtronic PLC's net income of $1.1B is higher than Stryker's net income of $654M. Notably, Medtronic PLC's price-to-earnings ratio is 24.70x while Stryker's PE ratio is 53.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.44x versus 6.56x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 11.83% compared to Medtronic PLC's net margin of -55.69%. Medtronic PLC's return on equity of 9.51% beat Tandem Diabetes Care's return on equity of -81.14%.

Medtronic PLC has a consensus price target of $96.73, signalling upside risk potential of 8.2%. On the other hand Tandem Diabetes Care has an analysts' consensus of $32.20 which suggests that it could grow by 99.13%. Given that Tandem Diabetes Care has higher upside potential than Medtronic PLC, analysts believe Tandem Diabetes Care is more attractive than Medtronic PLC.

Medtronic PLC has a beta of 0.804, which suggesting that the stock is 19.64% less volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.478, suggesting its more volatile than the S&P 500 by 47.763%.

Medtronic PLC has a quarterly dividend of $0.71 per share corresponding to a yield of 3.14%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 76.98% of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Medtronic PLC quarterly revenues are $8.9B, which are larger than Tandem Diabetes Care quarterly revenues of $234.4M. Medtronic PLC's net income of $1.1B is higher than Tandem Diabetes Care's net income of -$130.6M. Notably, Medtronic PLC's price-to-earnings ratio is 24.70x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.44x versus 1.08x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.